RE:RE:RE:The effect of rate hikes...WELL isn't really a digital health stock. They are a digital health stock like Canadian Tire is an ecommerce play, only around the edges.
Pure plays are generally valued higher. That said, I have no opinion on Teledoc at this point, and my opinion on WELL is well documented here. Which, for the record is:
- I don't hate the company, I believe it is structurally overly complicated to "manage numbers" to show continued growth. The acquisitions at the corporate level appear opportunistic, though the ones at the subsidiary level look more disciplined;
- Based on DCF, I think that WELL is fully valued.
- The one point that I make that could be seen as "bashing" is that I see "penny stock pumper" behaviour from WELL. In particular, odd press releases from a company that purports to be grown up (earnings pre-releases and untimely earnings releases). Whenever I have seen this in the past, it has never ended well.
Noshortsallowed wrote: You don't have an answer then. What do you say to the investor who wants to invest in digital healthcare in a "high" interest rate market and they are looking at Teledoc with projected -1.60 EPS for 2022 and WELL which is projected to be positive EPS this year with merely one quarter the revenue of that company which is more than 10x our market cap. Which is the better buy in with interest rates as horrifying as they are for you?